Taipei, Taiwan, 1 March 2023 -- Lotus Pharmaceutical (1795:TT, the “Company”), a multinational pharmaceutical company, today announced the launch of its Vinorelbine soft gel capsules 20mg and 80mg in Vietnam, and currently is the first and only approved generic Vinorelbine soft gel in the market by the Drug Authority of Vietnam (DAV).
Vinorelbine is a vinca alkaloid indicated in combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC); as a single agent for first-line treatment of patients with metastatic NSCLC.
Petar Vazharov, Chief Executive Officer of Lotus, said: “After Launching the product in more than 20 countries in Asia and Europe, Lotus is now proud to launch Vinorelbine soft gel capsule in Vietnam. The successful launch in Vietnam forms the backbone of Lotus’s oncology franchise in Vietnam and create valuable synergies among the oncology portfolio and bring our high-quality products to patients in the country”.
Vinorelbine soft gel capsule indications include breast cancer and non-small cell lung cancer (NSCLC). According to IQVIA data, the total sales of Vinorelbine soft gel worldwide were approximately US$ 180 million in 2021. Vietnam has been a leading market with a 7.5% growth rate for the last three years.